Oncology News Central

20 hours ago | oncologynewscentral.com | Youssef Rddad

On May 15, the U.S. Food and Drug Administration (FDA) approved frontline retifanlimab-dlwr (Zynyz) plus platinum-based chemotherapy for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The agency also approved retifanlimab as monotherapy for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

1 day ago | oncologynewscentral.com | Youssef Rddad

On May 14, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) for adults and children age 12 years and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma (PPGL). The approval of belzutifan, an HIF-2α inhibitor, marks the first oral treatment to be approved by the FDA for PPGL. The agency based its decision on results from the open-label, phase 2 LITESPARK-015 clinical trial.

1 day ago | oncologynewscentral.com | Youssef Rddad

On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for adults with previously treated, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.The antibody-drug conjugate is the first treatment approved for this patient population with NSCLC, according to a news release from the manufacturer, AbbVie.

2 days ago | oncologynewscentral.com | Racheal Ede

Exposure to colibactin bacteria in early childhood was associated with early-onset colorectal cancer (EOCRC) as colibactin-induced mutations were 3.3 times more prevalent in individuals diagnosed before age 40, compared to those above 70, according to a global study. The growing incidence of early-onset colorectal cancer over the past two decades has raised significant questions about its underlying causes and specific risk factors.

1 week ago | oncologynewscentral.com | Youssef Rddad

The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received previous systemic therapy. This marks the first-ever FDA approval for this disease, according to a statement from the manufacturer, Verastem Oncology. The FDA based its decision on results from the open-label, multicenter, single-group, phase 2 RAMP 201 clinical trial.